|
1
|
Global Asthma Network. Global asthma
report 2018. http://www.globalasthmanetwork.org. Accessed October
14, 2020.
|
|
2
|
British Thoracic Society; Scottish
Intercollegiate Guidelines Network. British guideline on the
management of asthma. Thorax. 58 (Suppl 1):i1–i94. 2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Turner S, Paton J, Higgins B and Douglas
G: British Guidelines on the Management of Asthma. British
guidelines on the management of asthma: what's new for 2011?
Thorax. 66:1104–1105. 2011.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kang JY, Kim JW, Kim JS, Kim SJ, Lee SH,
Kwon SS, Kim YK, Moon HS, Song JS, Park SH and Lee SY: Inhibitory
effects of anti-immunoglobulin E antibodies on airway remodeling in
a murine model of chronic asthma. J Asthma. 47:374–380.
2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Deng YM, Xie QM, Tang HF, Sun JG, Deng JF,
Chen JQ and Yang SY: Effects of ciclamilast, a new PDE 4 PDE4
inhibitor, on airway hyperresponsiveness, PDE4D expression and
airway inflammation in a murine model of asthma. Eur J Pharmacol.
547:125–135. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Sun JG, Deng YM, Wu X, Tang HF, Deng JF,
Chen JQ, Yang SY and Xie QM: Inhibition of phosphodiesterase
activity, airway inflammation and hyperresponsiveness by PDE4
inhibitor and glucocorticoid in a murine model of allergic asthma.
Life Sci. 79:2077–2085. 2006.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Charbe NB, Amnerkar ND, Ramesh B,
Tambuwala MM, Bakshi HA, Aljabali AAA, Khadse SC, Satheeshkumar R,
Satija S, Metha M, et al: Small interfering RNA for cancer
treatment: Overcoming hurdles in delivery. Acta Pharm Sin B.
10:2075–2109. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Corren J: Cytokine inhibition in severe
asthma: Current knowledge and future directions. Curr Opin Pulm
Med. 17:29–33. 2011.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Barnes PJ: Cytokine-directed therapies for
the treatment of chronic airway diseases. Cytokine Growth Factor
Rev. 14:511–522. 2003.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Holgate ST: Cytokine and anti-cytokine
therapy for the treatment of asthma and allergic disease. Cytokine.
28:152–157. 2004.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Walsh GM: Targeting eosinophils in asthma:
Current and future state of cytokine- and chemokine-directed
monoclonal therapy. Expert Rev Clin Immunol. 6:701–704.
2010.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Strasner AB, Natarajan M, Doman T, Key D,
August A and Henderson AJ: The Src kinase Lck facilitates assembly
of HIV-1 at the plasma membrane. J Immunol. 181:3706–3713.
2008.PubMed/NCBI View Article : Google Scholar
|
|
13
|
NCBI: Rattus norvegicus SRC
proto-oncogene, non-receptor tyrosine kinase (Src), mRNA. NCBI
Reference Sequence NM_031977.1. https://www.ncbi.nlm.nih.gov/nuccore/14010834/.
Accessed June 5, 2018.
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lee JU, Kim JD and Park CS:
Gene-environment interactions in asthma: Genetic and epigenetic
effects. Yonsei Med J. 56:877–886. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Gallelli L, Busceti MT, Vatrella A,
Maselli R and Pelaia G: Update on anticytokine treatment for
asthma. Biomed Res Int. 2013(104315)2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Guo S and Kemphues KJ: par-1, a gene
required for establishing polarity in C. elegans embryos, encodes a
putative Ser/Thr kinase that is asymmetrically distributed. Cell.
81:611–620. 1995.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in caenorhabditis elegans. Nature. 391:806–811.
1998.PubMed/NCBI View
Article : Google Scholar
|
|
19
|
Krymskaya VP, Goncharova EA, Ammit AJ, Lim
PN, Goncharov DA, Eszterhas A and Panettieri RA Jr: Src is
necessary and sufficient for human airway smooth muscle cell
proliferation and migration. FASEB J. 19:428–430. 2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
O'Keefe EP: siRNAs and shRNAs: Tools for
protein knockdown by gene silencing. Mater Methods. 3(197)2013.
|
|
21
|
McManus MT and Sharp PA: Gene silencing in
mammals by small interfering RNAs. Nat Rev Genet. 3:737–747.
2002.PubMed/NCBI View
Article : Google Scholar
|
|
22
|
McManus MT, Haines BB, Dillon CP,
Whitehurst CE, van Parijs L, Chen J and Sharp PA: Small interfering
RNA-mediated gene silencing in T lymphocytes. J Immunol.
169:5754–5760. 2002.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Xie Y, Kim NH, Nadithe V, Schalk D, Thakur
A, Kılıç A, Lum LG, Bassett DJP and Merkel OM: Targeted delivery of
siRNA to activated T cells via transferrin-polyethylenimine
(Tf-PEI) as a potential therapy of asthma. J Control Release.
229:120–129. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Choi M, Gu J, Lee M and Rhim T: A new
combination therapy for asthma using dual-function
dexamethasone-conjugated polyethylenimine and vitamin D binding
protein siRNA. Gene Ther. 24:727–734. 2017.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Leo C and Chen JD: The SRC family of
nuclear receptor coactivators. Gene. 245:1–11. 2000.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Liao L, Kuang SQ, Yuan Y, Gonzalez SM,
O'Malley BW and Xu J: Molecular structure and biological function
of the cancer-amplified nuclear receptor coactivator SRC-3/AIB1. J
Steroid Biochem Mol Biol. 83:3–14. 2002.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Xu J, Qiu Y, DeMayo FJ, Tsai SY, Tsai MJ
and O'Malley BW: Partial hormone resistance in mice with disruption
of the steroid receptor coactivator-1 (SRC-1) gene. Science.
279:1922–1925. 1998.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Karelina T, Voronova V, Demin O, Colice G
and Agoram BM: A mathematical modeling approach to understanding
the effect of anti-interleukin therapy on eosinophils. CPT
Pharmacometrics Syst Pharmacol. 5:608–616. 2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Jackson DJ, Makrinioti H, Rana BM, Shamji
BW, Trujillo-Torralbo MB, Footitt J, Del-Rosario J, Telcian AG,
Nikonova A, Zhu J, et al: IL-33-dependent type 2 inflammation
during rhinovirus-induced asthma exacerbations in vivo. Am J Respir
Crit Care Med. 190:1373–1382. 2014.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Barlow JL, Peel S, Fox J, Panova V,
Hardman CS, Camelo A, Bucks C, Wu X, Kane CM, Neill DR, et al:
IL-33 is more potent than IL-25 in provoking IL-13-producing
nuocytes (type 2 innate lymphoid cells) and airway contraction. J
Allergy Clin Immunol. 132:933–941. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Raundhal M, Morse C, Khare A, Oriss TB,
Milosevic J, Trudeau J, Huff R, Pilewski J, Holguin F, Kolls J, et
al: High IFN-γ and low SLPI mark severe asthma in mice and humans.
J Clin Invest. 125:3037–3050. 2015.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Leavy O: Asthma and allergy: An IFNγ bias
in severe asthma. Nat Rev Immunol. 15:466–467. 2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kawakami T and Galli SJ: Regulation of
mast-cell and basophil function and survival by IgE. Nat Rev
Immunol. 2:773–786. 2002.PubMed/NCBI View
Article : Google Scholar
|
